Previous Close | 0.1000 |
Open | N/A |
Bid | 0.0000 |
Ask | 4.5000 |
Strike | 7.00 |
Expire Date | 2024-10-18 |
Day's Range | 0.1000 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.